Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib 500mg vs 250mg in NSCLC with Stable Disease
NCT01017679Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- May 2009
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gefitinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate at 3 years. Started May 2009; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01017679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01017679.